Non-Hodgkin lymphoma (NHL) is a group of hematologic malignancies that originate from lymphocytes known as B or T cells. This ...
OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
Kidney damage is a serious complication affecting individuals with lupus, an autoimmune disease where immune B cells ...
ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...
1d
OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") ...
A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein ...
Researchers found that targeting cFLIP re-sensitized lymphoma cells to death signals in preclinical mouse models of DLBCL.
At AACR 2026, scientists showcased advances in radiotherapeutics, antibody-drug conjugates, T cell engagers, and ...
MSCs improve therapeutic consistency and precision across cell therapies. The approach also supports scalable allogeneic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results